US EditionNovo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial
4 Articles
4 Articles
Novo Nordisk (NVO) Stock Drops 15% After CagriSema Fails to Beat Eli Lilly's Zepbound
TLDR Novo Nordisk stock fell 15% after CagriSema failed to prove non-inferiority to Eli Lilly’s tirzepatide in an 84-week trial. CagriSema delivered 23% weight loss vs. 25.5% for tirzepatide — missing its primary endpoint. The stock hit its lowest level since June 2021, down nearly 50% over the past year. Novo’s CEO remains confident in CagriSema, citing its potential as the first GLP-1/amylin combo drug on the market. Eli Lilly stock rose 3.1%…
Novo Nordisk’s actions have plummeted this Monday to 16% in the Copenhagen Stock Exchange after it became known that CagriSema, his new experimental anti-obesity drug, has recorded failures in trials, a situation that reduces the impact on the weight loss market against its leading US competitor Eli Lilly, whose actions shot up 5%. The Danish firm’s drug produced a lower weight loss than its rival’s treatments. Read more: Novo Nordisk prepares f…
The Danish pharmaceutical company falls by about 15% in the patch after presenting the data from the trials of its new generation drug for obesity (CagriSema), which do not improve the weight loss figures offered by the rival drug Lilly (Zepbound). Read
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
